Skip to main content
xMedica

NCT05922878ClinicalTrials.gov

Study of ALTO-300 in MDD

A Randomized, Double-Blind, Placebo-Controlled Study of ALTO-300 With an Open-Label Extension in Adults With Major Depressive Disorder

RecruitingTaking participants now, according to the registry record.
Contact this study

In brief

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

Phase 2325 participants sought75 sites1 country

Categories

Registered in 1 registry

One study can be registered in several registries. We show it once and link every record we hold.

Trial information is shown as published by the registry, in its original language.

Interested in this study?

Sign in or create an account to register your interest and follow this study.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 20 days after the recorded start)First posted 2023-06-28; recorded start 2023-06-08
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 4 other studies in this databaseCounted from the lead sponsor named in the record (Alto Neuroscience)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 2 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 45 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 325 participants (target), run at 75 sites.

How this score is built
  • Enrolment24/40

    321 participants (target)

  • Site count19/25

    45 sites

  • Country count0/15

    Single country

  • Planned duration8/10

    Planned over about 42 months

  • Sponsor scale2/10

    Alto Neuroscience has led 5 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Summary

The purpose of this study is to determine efficacy differences between ALTO-300 and placebo, used adjunctively to an antidepressant, related to patient characteristics.

Conditions

  • Major Depressive Disorder

Eligibility

Eligibility
SexAll
Ages18 Years – 70 Years
Healthy volunteersNo

Eligibility as written in the registry

Inclusion Criteria: * Have a diagnosis of moderate to severe major depressive disorder (MDD) * At Visit 1, currently taking a stable dose of 1 or 2 antidepressants (e.g., SSRI, SNRI, bupropion, or gepirone) for at least 6 weeks with no dose modifications in the past 2 weeks by Visit 2 * Willing to comply with all study assessments and procedures * Must not be pregnant or breastfeeding at time of enrollment or throughout study Exclusion Criteria: * Evidence of unstable medical condition * Nightly use of sleep medication * Diagnosed bipolar disorder, psychotic disorder, or dementia * Current moderate or severe substance use disorder * Has a history of hypersensitivity or allergic reaction to ALTO-300 or any of its components/excipients * Concurrent or recent participation in another clinical trial for mental illness involving an investigational product or device

Eligibility in plain statements

This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.

Study design

Study design
Study typeInterventional
PhasePhase 2
AllocationRandomised
Intervention modelPARALLEL
Primary purposeTREATMENT
MaskingQUADRUPLE (4)
Enrolment325 participants sought

Sponsor and collaborators

  • Alto Neuroscience Sponsor

Arms and interventions

  • ALTO-300EXPERIMENTAL

    Participants will receive ALTO-300 25mg capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period. Eligible participants who will enter the open-label (OL) treatment period will receive ALTO-300 capsule once daily in the evening from OL baseline until the end of OL period/early termination visit (Up to 8 weeks).

  • PlaceboPLACEBO_COMPARATOR

    Participants will receive matching placebo capsule once daily in the evening, from Day 1 to Day 42 in double blind (DB) treatment period.

Interventions

  • Drug ALTO-300

    ALTO-300 capsule QD

  • Drug Placebo

    Placebo capsule QD

Outcome measures

  1. Primary outcome

    To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in a pre-defined subgroup of participants as measured by the change over time up to week 6 in the Montgomery-Ã…sberg Depression Rating Scale (MADRS).

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    Time frame Change over time for up to week 6

  2. Secondary outcome

    To assess efficacy of adjunctive ALTO-300 versus placebo on symptoms of MDD in all randomized participants as measured by the change over time up to week 6 in the Montgomery-Ã…sberg Depression Rating Scale (MADRS)

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    Time frame Change over time for up to week 6

  3. Secondary outcome

    To assess efficacy of adjunctive ALTO-300 versus placebo for MDD as measured by the change over time up to week 6 in response (>50% improvement from baseline) rates based on the MADRS

    MADRS is a clinician-administered scale designed to measure depression severity and detects changes due to antidepressant treatment. The MADRS evaluates the following 10 items: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts. Each item is scored from 0 (item not present or normal) to 6 (severe or continuous presence of the symptoms), for a total possible score of 60. Higher scores represent a more severe condition.

    Time frame Change over time for up to week 6

  4. Secondary outcome

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of the incidence, severity, and relatedness of Adverse Events.

    Incidence, severity, and relatedness of Adverse Events

    Time frame Assessed from Day 1 to Week 14

  5. Secondary outcome

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Heart Rate.

    Assessment of Heart Rate

    Time frame Assessed from Day 1 to Week 14

  6. Secondary outcome

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Weight.

    Assessment of Weight Change

    Time frame Assessed from Day 1 to Week 14

  7. Secondary outcome

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of Blood Pressure.

    Assessment of Blood Pressure

    Time frame Assessed from Day 1 to Week 14

  8. Secondary outcome

    To evaluate the safety of ALTO-300 during both the OL and DB periods of the study as measured by the assessment of suicidality with the Concise Health Risk Tracking Self-Report,12 item scale (CHRT-SR12).

    The CHRT is a brief, self-report measure that systematically assesses both suicidal thinking and associated thoughts that may indicate the propensity for suicidal acts. The CHRT-SR12 is a 12 item scale. The patient assigns a score of 0-4 for each item of the scale, allowing for a total score of 0 to 48, with the higher score signifying more severe symptoms.

    Time frame Assessed from Day 1 to Week 15

Dates

Dates
Start dateJune 8, 2023 (actual)
Primary completionDecember 1, 2026 (estimated)
CompletionDecember 1, 2026 (estimated)
First postedJune 28, 2023 (actual)
Last updatedOctober 26, 2026
Results postedNot stated in the registry record
Status last verifiedOctober 2026

Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.

Locations

30 sites are recruiting

United States

United States
FacilityCityState or regionStatus
Site 114AlbuquerqueNew MexicoRecruiting
Site 216AllentownPennsylvaniaTerminated
Site 316AustinTexasRecruiting
Site 218BellflowerCaliforniaRecruiting
Site 317BlackfootIdahoWithdrawn
Site 236BoiseIdahoRecruiting
Site 119BoiseIdahoActive, not recruiting
Site 318CarlsbadCaliforniaActive, not recruiting
Site 310ChicagoIllinoisActive, not recruiting
Site 202CincinnatiOhioRecruiting
Site 159ClermontFloridaTerminated
Site 207ClintonUtahActive, not recruiting
Site 203Colorado SpringsColoradoActive, not recruiting
Site 239ConroeTexasRecruiting
Site 229Creve CouerMissouriWithdrawn
Site 102DallasTexasActive, not recruiting
Site 343DenverColoradoRecruiting
Site 349EvergreenColoradoActive, not recruiting
Site 345EvergreenColoradoActive, not recruiting
Site 277FairfaxVirginiaRecruiting
Site 238FayettevilleGeorgiaRecruiting
Site 148Fort WorthTexasWithdrawn
Site 347Fort WorthTexasTerminated
Site 217GlendaleCaliforniaActive, not recruiting
Site 279HattiesburgMississippiWithdrawn
Site 199HickoryNorth CarolinaActive, not recruiting
Site 320HoustonTexasRecruiting
Site 275HoustonTexasRecruiting
Site 215JacksonMississippiActive, not recruiting
Site 335LafayetteCaliforniaRecruiting
Site 335LafayetteCaliforniaRecruiting
Site 344Las VegasNevadaRecruiting
Site 209Los AngelesCaliforniaActive, not recruiting
Site 240MankatoMinnesotaRecruiting
Site 201MarreroLouisianaTerminated
Site 219MatherCaliforniaRecruiting
Site 350MediaPennsylvaniaWithdrawn
Site 225Miami GardensFloridaActive, not recruiting
Site 190Miami LakesFloridaActive, not recruiting
Site 265MinneapolisMinnesotaRecruiting
Site 194Mission ViejoCaliforniaTerminated
Site 206Missouri CityTexasWithdrawn
Site 198MonroeLouisianaTerminated
Site 267MoorparkCaliforniaRecruiting
Site 352MoosicPennsylvaniaActive, not recruiting
Site 283New YorkNew YorkRecruiting
Site 319New YorkNew YorkActive, not recruiting
Site 214NorwalkConnecticutWithdrawn
Site 161OkeechobeeFloridaActive, not recruiting
Site 195Oklahoma CityOklahomaTerminated

25 further sites are listed in the registry record.

Study documents

No documents are linked in this registry record.

Changes over time

  1. October 26, 2026

    Enrolment target changed

    Enrollment target revised up from 321 to 325

    321325

  2. October 26, 2026

    Site added

    30 sites added (75 total)

    4575